Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 23426401.
- Also identified by DOI 10.1038/nrc3432 and PMC identifier 4673904.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Malignant ascites presents a considerable clinical challenge to the management of ovarian cancer, but also provides a wealth of opportunities for translational research. The accessibility of ascitic fluid and its cellular components make it an excellent source of tumour tissue for the investigation of prognostic and predictive biomarkers, pharmacodynamic markers and for molecular profiling analysis. In this Opinion article, we discuss recent advances in our understanding of its pathophysiology, the development of new methods to characterize its molecular features and how these findings can be used to improve the treatment of malignant ascites, particularly in the context of ovarian cancer.
Medical subject headings
- Ascites
- Ovarian Neoplasms